Repudi SR, Patra M, Sen M
Activation of the SIRT6-AMPK signaling pathway by GLP-1RAs may therefore represent an attractive therapeutic strategy to prevent the development and progression of NAFLD and related cardiovascular diseases by modulating cholesterol metabolism
The major medication is ursodeoxycholic [er-sudi- oxy -cholic] acid (UDCA), as synthetic bile acid
Reference: Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society Mozaffarian, Dariush et al
Diabetologia 52:199207 Kang ZF, Deng Y, Zhou Y et al (2012) In mouse models of diabetes, pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through glucagon-like peptide 1 receptor signalling in the beta cell
Similarly, BC-Lipo (33.41 3.34% total